MNKPF News and Press, Mallinckrodt From 09/28/22

Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System PR Newswire — If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel del...

Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer PR Newswire DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, tod...

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) PR Newswire – Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney func...

Mallinckrodt plc Provides Update on Executive Committee PR Newswire DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today provided an upda...

Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors PR Newswire DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, tod...

Mallinckrodt press release ( NYSE: MNK ): Q2 net loss of $257.2M Revenue of $468.7M (-14.2% Y/Y). Bryan Reasons, EVP and Chief Financial Officer, said, "Having eliminated more than $1.3 billion in debt principal and closed a new $200 million accounts receivable financi...

Mallinckrodt plc Reports Second Quarter 2022 Financial Results and Provides 2022 Financial Guidance PR Newswire Focused on Advancing Branded Pipeline with Anticipated Launches and Bringing Existing Products to New Markets and Geographies Committed to Strengthen...

MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it wil...